

Online Supplement

Perceived Stress is Associated with Health Outcomes, Platelet Activation, and Oxidative Stress in COPD

Obiageli Offor, MD, MPH¹ Michelle N. Eakin, PhD¹ Han Woo, PhD¹ Daniel Belz, MD, MPH¹
Marlene Williams, MD² Sarath Raju, MD, MPH¹ Meredith McCormack, MD, MHS¹ Nadia N.
Hansel, MD, MPH¹ Nirupama Putcha, MD, MHS¹ Ashraf Fawzy, MD, MPH¹

¹Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, Maryland, United States

²Division of Cardiology, Johns Hopkins University, Baltimore, Maryland, United States


Address correspondence to:

Obiageli Offor, MD, MPH
Division of Pulmonary and Critical Care
Johns Hopkins University
Baltimore, Maryland
Email: ooffor1@jhmi.edu

Supplemental Online Materials

1. Supplemental Figure 1: Flow of participants between perceived stress score categories low (0-13), medium (14-26), and high (27-40) during the 6-month study period
2. Supplemental Table 1. Effect Estimates of the Association Between a 4-point increment in Perceived Stress Score with COPD Morbidity
3. Supplemental Table 2. Effect Estimates of the Association Between Perceived Stress Score Categories with COPD Morbidity
4. Supplemental Table 3. Sensitivity Analysis of the individual and combined effects of symptoms of Depression or Anxiety, Food insecurity and Area Deprivation index on the Association of Perceived Stress Score on Respiratory Outcomes
5. Supplemental Table 4. Mean Difference with 95% confidence intervals and interaction p-values of the Association Between a 4-point increment in Perceived Stress Score with Biomarkers stratified by COPD severity.
6. Supplemental Table 5. Effect Estimates of the Association Between Perceived Stress Score Categories with Biomarkers.

Supplemental Figure 1: Flow of participants between perceived stress score categories low (0-13), medium (14-26), and high (27-40) during the 6-month study period



Supplemental Table 1. Effect Estimates of the Association Between a 4-point increment in Perceived Stress Score with COPD Morbidity

	All Participants	GOLD\leq2	GOLD\geq3
Respiratory symptoms	Mean Difference (95% CI)	Mean Difference (95% CI)	Mean Difference (95% CI)
CAT	0.91 (0.40, 1.43)	0.49 (-0.15, 1.12)	1.50 (0.74, 2.25)
mMRC	0.03 (-0.05, 0.10)	0.01 (-0.08, 0.09)	0.11 (0.01, 0.22)
SGRQ	2.17 (1.21, 3.13)	1.07 (-0.03, 2.18)	3.95 (2.39, 5.52)
CCQ	0.11 (0.05, 0.17)	0.03 (-0.03, 0.10)	0.22 (0.13, 0.32)
ECSC	0.36 (0.11, 0.61)	0.17 (-0.17, 0.51)	0.64 (0.38, 0.56)
Exacerbations*	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)
Any	1.17 (0.96, 1.42)	1.28 (0.92, 1.78)	1.04 (0.81, 1.33)
Moderate/Severe	1.11 (0.90, 1.37)	1.32 (1.00, 1.76)	1.01 (0.75, 1.35)

CAT = COPD Assessment Test; mMRC = Modified Medical Research Council Questionnaire; SGRQ = St. George's Respiratory Questionnaire; CCQ = Clinical COPD Questionnaire; ECSC: Ease of Cough and Sputum Clearance Questionnaire. *Exacerbations assessed as having at least 1 exacerbation over the 12-month study period (yes/no) using repeated measures of PSS scores collected at each study visit.

Supplemental Table 2. Effect Estimates of the Association Between Perceived Stress Score Categories with COPD Morbidity

	All Participants		GOLD<2		GOLD≥3	
	Moderate Stress	High Stress	Moderate Stress	High Stress	Moderate Stress	High Stress
	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)
Respiratory Symptoms						
CAT	2.39 (0.80, 3.97)	7.86 (5.10, 10.63)	0.84 (-1.05, 2.74)	6.04 (3.06, 9.02)	3.87 (1.47, 6.27)	14.60 (11.72, 17.48)
mMRC	0.20 (-0.05, 0.44)	0.18 (-0.31, 0.68)	0.02 (-0.25, 0.29)	0.35 (-0.15, 0.86)	0.53 (0.16, 0.90)	0.25 (-0.64, 1.15)
SGRQ	3.38 (-0.02, 6.78)	12.04 (5.60, 18.47)	-0.60 (-4.68, 3.49)	6.89 (0.16, 13.63)	9.16 (4.38, 13.93)	29.96 (23.38, 36.54)
CCQ	0.29 (0.07, 0.52)	0.70 (0.38, 1.02)	0.02 (-0.23, 0.27)	0.48 (0.22, 0.74)	0.60 (0.232, 0.97)	1.62 (1.17, 2.08)
ECSC	1.46 (0.63, 2.28)	3.20 (1.41, 4.99)	0.95 (-0.22, 2.12)	2.35 (0.04, 4.65)	2.00 (0.99, 3.01)	5.19 (4.00, 6.38)
Exacerbations*	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)
Any	0.95 (0.52, 1.74)	3.90 (0.83, 18.2)	0.90 (0.35, 2.28)	2.95 (0.21, 41.13)	0.74 (0.31, 1.76)	2.03 (0.14, 28.61)
Moderate/Severe	0.77 (0.37, 1.57)	4.15 (1.28, 13.47)	1.10 (0.29, 4.19)	2.45 (0.28, 21.63)	0.45 (0.18, 1.12)	5.89 (0.93, 37.37)

Reference group is Low Stress (PSS 0-13). CAT = COPD Assessment Test; mMRC = Modified Medical Research Council Questionnaire; SGRQ = St. George's Respiratory Questionnaire; CCQ = Clinical COPD Questionnaire; ECSC: Ease of Cough and Sputum Clearance Questionnaire. *Exacerbations assessed as having at least 1 exacerbation over the 12-month study period (yes/no) using repeated measures of PSS scores collected at each study visit.

Supplemental Table 3. Sensitivity Analysis of the individual and combined effects of symptoms of Depression or Anxiety, Food insecurity and Area Deprivation index on the Association of Perceived Stress Score on Respiratory Outcomes

	Depression or Anxiety	Food insecurity	Area Deprivation Index	Combined Effects
Respiratory symptoms	Mean Difference (95% CI)	Mean Difference (95% CI)	Mean Difference (95% CI)	Mean Difference (95% CI)
CAT	0.84 (0.28, 1.40)	0.89 (0.37, 1.41)	0.91 (0.40, 1.43)	0.80 (0.24, 1.37)
mMRC	0.01 (-0.06, 0.09)	0.02 (-0.06, 0.09)	0.03 (-0.04, 0.10)	0.004 (-0.07, 0.08)
SGRQ	1.96 (0.93, 2.99)	2.14 (1.16, 3.12)	2.21 (1.24, 3.17)	1.99 (0.95, 3.04)
CCQ	0.09 (0.02, 0.15)	0.11 (0.04, 0.17)	0.11 (0.05, 0.17)	0.08 (0.02, 0.15)
ECSC	0.30 (0.03, 0.58)	0.36 (0.10, 0.61)	0.37 (0.11, 0.62)	0.30 (0.03, 0.58)
Exacerbations*	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)
Any	1.17 (0.95, 1.44)	1.15 (0.94, 1.40)	1.19 (0.98, 1.45)	1.14 (0.96, 1.37)
Moderate/Severe	1.16 (0.93, 1.45)	1.08 (0.87, 1.34)	1.13 (0.92, 1.38)	1.12 (0.98, 1.27)

CAT = COPD Assessment Test; mMRC = Modified Medical Research Council Questionnaire; SGRQ = St. George's Respiratory Questionnaire; CCQ = Clinical COPD Questionnaire; ECSC: Ease of Cough and Sputum Clearance Questionnaire. *Exacerbations assessed as having at least 1 exacerbation over the 12-month study period (yes/no) using repeated measures of PSS scores collected at each study visit.

Supplemental Table 4. Mean Difference with 95% confidence intervals and interaction p-values of the Association Between a 4-point increment in Perceived Stress Score with Biomarkers stratified by COPD severity.

	All Participants	Mild-Moderate COPD (GOLD\leq2)	Severe COPD (GOLD\geq3)	Interaction P-value
Platelet activation				

Urine 11-dehydro-Thromboxane B2 (pg/mg Creatinine)	2.8 (-0.5, 6.3)	6.0 (1.6, 10.6)	-1.3 (-6.3, 4.0)	0.14
Oxidative stress				
Urine TBARS (um/mg Creatinine)	-2.1 (-5.8, 1.6)	1.1 (-3.4, 5.8)	-6.5 (-11.6, -1.0)	0.07
Urine 8OHdG (ng/mg Creatinine)	-0.3 (-3.8, 3.3)	2.0 (-3.1, 7.4)	-3.4 (-9.4, 3.0)	0.13
Urine 8-Isoprostane (pg/mg Creatinine)	1.9 (-1.6, 5.5)	4.9 (-0.7, 9.3)	-2.6 (-7.7, 2.8)	0.06
Inflammation				
TNF- α (pg/ml)	0.7 (-0.6, 1.9)	0.7 (-1.0, 2.5)	0.1 (-1.6, 1.8)	0.99
Interleukin 6 (pg/ml)	2.8 (-3.5, 9.6)	2.8 (-6.8, 13.3)	5.1 (-1.8, 12.5)	0.52
Interleukin 8 (pg/ml)	-0.7 (-3.2, 1.8)	0.2 (-2.7, 3.2)	-2.5 (-6.6, 1.9)	0.17
IFN- γ (pg/ml)	-0.6 (-5.6, 4.7)	2.2 (-10.2, 6.5)	-2.2 (-6.4, 5.7)	0.39

TBARS= Thiobarbituric acid reactive species; 8-OHdG= 8-hydroxydeoxyguanosine

Supplemental Table 5. Effect Estimates of the Association Between Perceived Stress Score Categories with Biomarkers.

	All Participants		GOLD\leq2		GOLD\geq3	
	Moderate Stress	High Stress	Moderate Stress	High Stress	Moderate Stress	High Stress
	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)
Platelet activation						
Urine Thromboxane B2 (pg/mg Creatinine)	8.7 (-6.3, 26.1)	25.1 (-0.3, 56.9)	20.1 (3.1, 40.0)	52.9 (22.1, 91.6)	-10.7 (-31.9, 17.1)	-11.6 (-30.9, 13.2)
Oxidative Stress						
Urine TBARS (um/mg Creatinine)	0.3 (-12.9, 15.5)	-25.5 (-43.8, -1.2)	-2.2 (-19.6, 19.0)	-9.0 (-33.8, 25.2)	3.0 (-13.1, 22.1)	-53.9 (-64.8, -39.7)
Urine 8OHdG (ng/mg Creatinine)	-6.1 (-18.9, 8.8)	-0.2 (-28.7, 39.5)	-3.0 (-20.9, 19.0)	5.5 (-37.1, 76.9)	-13.8 (-31.6, 8.7)	-0.8 (-30.5, 41.7)
Urine 8-Isoprostane (pg/mg Creatinine)	-3.9 (-16.2, 10.1)	40.1 (11.5, 76.0)	6.7 (-8.3, 24.3)	59.4 (20.6, 110.8)	-18.5 (-35.2, 2.5)	16.7 (-10.9, 52.9)
Inflammation						
TNF- α (pg/ml)	1.6 (-3.7, 7.2)	0.8 (-8.4, 10.9)	4.3 (-2.3, 11.4)	1.6 (-9.3, 13.8)	-1.2 (-8.0, 6.0)	-2.3 (-20.1, 19.6)
Interleukin 6 (pg/ml)	7.3 (-12.4, 31.5)	12.9 (-34.7, 95.2)	1.6 (-24.8, 37.2)	-3.4 (-49.9, 86.5)	15.6 (-13.6, 54.6)	47.9 (-11.8, 147.8)
Interleukin 8 (pg/ml)	0.3 (-9.0, 10.6)	6.7 (-8.5, 24.3)	3.6 (-6.9, 15.3)	11.5 (-5.5, 31.5)	-7.4 (-24.4, 13.5)	-15.1 (-30.1, 3.1)
IFN- γ (pg/ml)	-4.7 (-21.3, 15.3)	-13.9 (-44.5, 33.5)	-0.9 (-21.4, 24.9)	2.7 (-40.9, 78.6)	-5.6 (-33.8, 34.6)	-18.7 (-65.4, 91.1)

Reference group is Low Stress (PSS 0-13). TBARS= Thiobarbituric acid reactive species; 8-OHdG= 8-hydroxydeoxyguanosine

